{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:22:03Z","timestamp":1787851323947,"version":"build-2784847793"},"reference-count":45,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005615","name":"Beth Israel Deaconess Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005615","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.esmoop.2026.107774","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T18:46:59Z","timestamp":1784227619000},"page":"107774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of prior conventional irinotecan use on nanoliposomal irinotecan efficacy in advanced pancreatic cancer: a meta-analysis"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3023-1304","authenticated-orcid":false,"given":"S.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.L.","family":"Correa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Birda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9305-7679","authenticated-orcid":false,"given":"K.","family":"Roshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0905-7583","authenticated-orcid":false,"given":"M.L.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6543-4078","authenticated-orcid":false,"given":"A.M.","family":"Modest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3624-0079","authenticated-orcid":false,"given":"M.","family":"Keko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9162-1560","authenticated-orcid":false,"given":"B.","family":"Bockorny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.esmoop.2026.107774_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated projection of US cancer incidence and death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"19","key":"10.1016\/j.esmoop.2026.107774_bib2","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.esmoop.2026.107774_bib3","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2026.107774_bib4","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s40265-017-0741-1","article-title":"Liposomal irinotecan: a review in metastatic pancreatic adenocarcinoma","volume":"77","author":"Lamb","year":"2017","journal-title":"Drugs"},{"issue":"23","key":"10.1016\/j.esmoop.2026.107774_bib5","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1158\/0008-5472.CAN-14-0572","article-title":"Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion","volume":"74","author":"Kalra","year":"2014","journal-title":"Cancer Res"},{"issue":"10018","key":"10.1016\/j.esmoop.2026.107774_bib6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"issue":"10409","key":"10.1016\/j.esmoop.2026.107774_bib7","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.esmoop.2026.107774_bib8","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S1470-2045(25)00363-8","article-title":"Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial","volume":"26","author":"Janssen","year":"2025","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.esmoop.2026.107774_bib9","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.esmoop.2026.107774_bib10","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107774_bib11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/MPA.0000000000001479","article-title":"Real-world dosing patterns and outcomes of patients with metastatic pancreatic cancer treated with a liposomal irinotecan regimen in the United States","volume":"49","author":"Barzi","year":"2020","journal-title":"Pancreas"},{"key":"10.1016\/j.esmoop.2026.107774_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919871126","article-title":"Real-world efficacy and safety of liposomal irinotecan plus fluorouracil\/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group","volume":"11","author":"Yoo","year":"2019","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107774_bib13","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/jhbp.1128","article-title":"Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin","volume":"29","author":"Chiu","year":"2022","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"8","key":"10.1016\/j.esmoop.2026.107774_bib14","doi-asserted-by":"crossref","first-page":"9496","DOI":"10.1002\/cam4.5714","article-title":"Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma","volume":"12","author":"Yu","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.esmoop.2026.107774_bib15","series-title":"The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","author":"Wells","year":"2011"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107774_bib16","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12967-020-02404-x","article-title":"Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"18","author":"An","year":"2020","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107774_bib17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jpainsymman.2020.07.037","article-title":"Prevalence of fatigue in patients with cancer: a systematic review and meta-analysis","volume":"61","author":"Al Maqbali","year":"2021","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.esmoop.2026.107774_bib18","unstructured":"WebPlotDigitizer [computer program]. Version 5.2. Rohatgi A; 2021."},{"key":"10.1016\/j.esmoop.2026.107774_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan\u2013Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107774_bib20","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/jrsm.1259","article-title":"Methods for including information from multi-arm trials in pairwise meta-analysis","volume":"8","author":"R\u00fccker","year":"2017","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.esmoop.2026.107774_bib21","series-title":"R: A Language and Environment for Statistical Computing [computer program]","year":"2023"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107774_bib22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"10.1016\/j.esmoop.2026.107774_bib23","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"Assessing risk of bias due to missing evidence in a meta-analysis","author":"Page","year":"2024"},{"issue":"7","key":"10.1016\/j.esmoop.2026.107774_bib24","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1177\/21925682221110527","article-title":"Fixed-effect vs random-effects models for meta-analysis: 3 points to consider","volume":"12","author":"Dettori","year":"2022","journal-title":"Global Spine J"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107774_bib25","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1186\/s12885-018-4605-1","article-title":"Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience","volume":"18","author":"Glassman","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmoop.2026.107774_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221119539","article-title":"A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma","volume":"14","author":"Chun","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107774_bib27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/JCMA.0000000000000650","article-title":"Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: a real-world experience","volume":"85","author":"Yu","year":"2022","journal-title":"J Chin Med Assoc"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107774_bib28","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3390\/jcm12041596","article-title":"Correlation of UGT1A1 gene polymorphisms or prior irinotecan treatment and treatment outcomes of nanoliposomal-irinotecan plus 5-fluorouracil\/leucovorin for pancreatic ductal adenocarcinoma: a multicenter, retrospective cohort study (HGCSG2101)","volume":"12","author":"Harada","year":"2023","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107774_bib29","doi-asserted-by":"crossref","first-page":"464","DOI":"10.21037\/jgo-20-338","article-title":"Efficacy and tolerability of the combination of nano-liposomal irinotecan and 5-fluorouracil\/leucovorin in advanced pancreatic adenocarcinoma: post-approval clinic experience","volume":"12","author":"Kasi","year":"2021","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107774_bib30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12885-023-10542-w","article-title":"Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil\/leucovorin","volume":"23","author":"Kawakami","year":"2023","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107774_bib31","doi-asserted-by":"crossref","first-page":"352","DOI":"10.21037\/jgo-22-632","article-title":"Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature","volume":"14","author":"M\u00f6hring","year":"2023","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.esmoop.2026.107774_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241279688","article-title":"Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil\/leucovorin: a multicenter observational study","volume":"16","author":"Keum","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107774_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-63172-y","article-title":"A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer","volume":"14","author":"Kodama","year":"2024","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107774_bib34","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s10147-023-02432-9","article-title":"Liposomal irinotecan plus fluorouracil\/leucovorin in older patients with advanced pancreatic cancer: a single-center retrospective study","volume":"29","author":"Nagashima","year":"2024","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107774_bib35","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s10147-024-02677-y","article-title":"Conditions for effective use of liposomal irinotecan with fluorouracil and leucovorin in unresectable pancreatic cancer after FOLFIRINOX treatment","volume":"30","author":"Okada","year":"2025","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107774_bib36","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/0008-5472.CAN-05-4007","article-title":"Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy","volume":"66","author":"Drummond","year":"2006","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.esmoop.2026.107774_bib37","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/annonc\/mdf337","article-title":"Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity","volume":"13","author":"Xu","year":"2002","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.107774_bib38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/0041-008X(73)90161-0","article-title":"Nitrilotriacetate (NTA): human metabolism and its importance in the total safety evaluation program","volume":"25","author":"Budny","year":"1973","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107774_bib39","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.pan.2025.08.007","article-title":"Cost-effectiveness of liposomal irinotecan (nal-IRI) combined with 5-fluorouracil and leucovorin in second or subsequent lines for metastatic pancreatic cancer in Italy. It can be done","volume":"25","author":"Giuliani","year":"2025","journal-title":"Pancreatology"},{"issue":"10","key":"10.1016\/j.esmoop.2026.107774_bib40","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12032-019-1309-6","article-title":"Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience","volume":"36","author":"Tossey","year":"2019","journal-title":"Med Oncol"},{"issue":"10409","key":"10.1016\/j.esmoop.2026.107774_bib41","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0140-6736(23)01521-0","article-title":"Treating metastatic pancreatic ductal adenocarcinoma: NALIRIFOX as new standard?","volume":"402","author":"Besselink","year":"2023","journal-title":"Lancet"},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2026.107774_bib42","article-title":"PCN108 The cost-effectiveness of liposomal irinotecan and 5-fluorouracil (5-FU)\/leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of pancreas WHO have progressed following the use of gemcitabine-related therapies in Greece","volume":"23","author":"Gourzoulidis","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.esmoop.2026.107774_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1596658","article-title":"Cost-effectiveness analysis of irinotecan hydrochloride liposome in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma","volume":"16","author":"Zhan","year":"2025","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107774_bib44","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40273-017-0592-3","article-title":"Pegylated liposomal irinotecan hydrochloride trihydrate for treating pancreatic cancer after gemcitabine: an evidence review group perspective of a NICE single technology appraisal","volume":"36","author":"Fleeman","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"21","key":"10.1016\/j.esmoop.2026.107774_bib45","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1002\/cncr.35479","article-title":"Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta-analysis of real-world evidence","volume":"130","author":"Gupta","year":"2024","journal-title":"Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926017163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926017163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:34:34Z","timestamp":1787848474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926017163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2059702926017163"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107774","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of prior conventional irinotecan use on nanoliposomal irinotecan efficacy in advanced pancreatic cancer: a meta-analysis","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107774","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"107774"}}